Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China.
Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Medicine (Baltimore). 2022 Oct 21;101(42):e31173. doi: 10.1097/MD.0000000000031173.
Behçet's disease (BD) is an autoimmune disease presented with recurrent oral aphthous ulcers, genital ulcers, uveitis and skin lesions. The cutaneous manifestations are often refractory and more resistant to conventional therapy. This report provides a new treatment of low-dose interleukin-2 (IL-2) with refractory BD patient.
A 37-year-old female patient experienced oral ulcer and erythema nodosum on the right leg for over 12 months and resisted to Methylprednisolone and Thalidomide.
The patient suffered from recurrent painful oral ulceration and an erythema nodosum. Pathergy test is also positive. Thus, we diagnosed her as BD according to the International Criteria for Behçet's Disease (ICBD).
The patient took Methylprednisolone 8 mg qd, Thalidomide 50 mg qn and Hydroxychloroquine 200 mg bid successively as treatment. However, the medicine didn't take effect. Finally, this patient was given low-dose IL-2 intramuscular injection qod for 3 months.
Oral ulcers and the erythema disappeared and the patient has been symptom-free for 6 months.
low-dose IL-2 is a safe and effective treatment for refractory BD.
贝赫切特病（BD）是一种自身免疫性疾病，表现为复发性口腔阿弗他溃疡、生殖器溃疡、葡萄膜炎和皮肤损伤。皮肤表现往往是难治性的，对常规治疗更具抵抗力。本报告提供了一种新的低剂量白细胞介素 2（IL-2）治疗难治性 BD 患者的方法。
一名 37 岁女性患者，口腔溃疡和右腿结节性红斑病史超过 12 个月，对甲泼尼龙和沙利度胺抵抗。
患者反复出现疼痛性口腔溃疡和结节性红斑。皮肤试验也呈阳性。因此，我们根据国际贝赫切特病诊断标准（ICBD）诊断她为 BD。
患者先后接受了甲泼尼龙 8mg qd、沙利度胺 50mg qn 和羟氯喹 200mg bid 的治疗。然而，药物没有起效。最后，该患者接受了低剂量白细胞介素 2 肌内注射 qod，共 3 个月。
口腔溃疡和红斑消失，患者无任何症状 6 个月。
低剂量白细胞介素 2 是治疗难治性 BD 的一种安全有效的方法。
